Deal Dynamics

Europe

Asia

Advisor Q&As

Beauty

Food & Beverage

Disruption

ESG

Lending

Innovation

E-Commerce

Outlook

Software

Cross-Border

Consolidation

Private Equity

COVID-19

Technology

Automotive

Companion Animal

Our Thinking

We provide strategic advisory utilizing deep industry expertise and unique market perspectives.

SIGNUP FOR OUR EMAIL UPDATES
Scrip | What Does 2023 Hold for Biopharma? Part 6: Artificial Intelligence

Originally posted by Scrip on February 10, 2023. Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for artificial intelligence in the biopharma industry. View the original article.

Scrip | What Does 2023 Hold for Biopharma?

Originally posted by Scrip on January 9, 2023. Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for biopharma mergers and acquisitions (M&A) trends in 2023. View the… Read More

What’s Old is New Again: Value-Based Care Delivery in the Home

In 1930, physicians visiting patients in their residences represented 40 percent of all encounters. 20 years later this figure had fallen dramatically to just one visit in 10. By the… Read More

In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners

Originally published by In Vivo Pharma Intelligence on November 15, 2022 James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the… Read More

Lincoln’s Latest

Lincoln’s Latest video series features experts from across industries, services and geographies, sharing perspectives on current trends, recent observations and future outlooks.

Surging Medical Inflation Fuels Continued Interest in Self-Funding and Cost Containment

During the past 18 months, inflation has accelerated to levels not seen since the early 1980s. The cost of energy, food and other staples has increased rapidly and is expected… Read More

Discovering the Investment Opportunity in Pre-Clinical CROs

The process to bring a drug to market is likely to be extensive and costly, from the starting points of research and development (R&D) across all phases of clinical trials… Read More

Reality Check: Assessing Private Equity’s 2022 Predictions

In Q4 2021, Lincoln International surveyed nearly 400 private equity investors on their expectations for dealmaking in the year ahead. In the three quarters since, public equity markets have seen… Read More

Lincoln Private Market Index Experiences First Decline Since Q1 2020

Public market volatility driven by heightened recession fears trickled to private market enterprise values in Q2 The Lincoln Private Market Index (Lincoln PMI), the only index that tracks changes in… Read More

Even as Possible Recession Looms, Prospects for Private Markets Look Strong

It is no secret that public markets are facing notable volatility. But from where I sit in the trenches of private market dealmaking, the near-term prospects for private equity remain… Read More

Business Insider | Healthcare Targets and Corporate Orphans Take Center Stage Amid a Dearth of M&A Activity

Originally published by Business Insider on August 2, 2022. Rob Brown, Global Chief Executive Officer of Lincoln International, discusses Amazon’s acquisition of One Medical and the state of the healthcare… Read More

Mint | Hospital investors line up over $2 bn in exits as covid-19 recedes

Originally published by Mint on May 16, 2022. Lincoln International’s Gaurav Marathe, Managing Director and CEO India, discusses hospital chain performance during the pandemic and future considerations for investors. Click here… Read More

Showing 1 – 12 of 52
Load More